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ABSTRACT
   The idea of using drug carriers to improve the therapeutic efÞ cacy 
of pharmacological agents is receiving increasing attention. The 
consequence of attachment of low molecular weight drugs to 
macromolecular carriers alters their rate of excretion from the body, 
changes their toxicity and immunogenicity and limits their uptake 
by cells via endocytosis, thus providing the opportunity to direct 
the drugs to the particular cell type where its activity is needed. In 
addition, these macromolecular conjugates can accumulate in solid 
tumors due to the enhanced microvasculature of the tumor tissue. This 
phenomenon has been termed enhanced permeability and retention 
(EPR-phenomenon) in relation to the tumor targeting. Such delivery 
systems can be usefully distinguished into the formulations of anti-
cancer drugs. In this paper we report on the synthesis of the poly(vinyl 
alcohol)-doxorubicin conjugates and the synthesis of the poly(vinyl 
alcohol)-paclitaxel conjugates, and their release experiment, tissue 



























































?????????????Fig. 1?Fig. 2???????????cis-ADOX? ?????? trans-
ADOX? ????????????????????????????????????????




















???????????????????? (15)???? PVA? DOX??????????
?????????????????????
Fig.2.  HPLC chromatogram of ADOX. Chromatography was carried out using a HPLC system 
equipped with a variable-wavelength ß uorescent detector. The excitation and emission wavelength 
were set at 470 nm and 560 nm, respectively. A 4.6 x 150 mm, 5-?m particle size, C18 reversed-
phase column was used at ambient temperature. The mobile phase was (NH4)2CO3 (3 w/w%): 
methanol : acetonitrile = 50 : 45 : 5, v/v/v. The injection volume was 20 ?l, and the ß ow rate was 1.0 




          
 
Fig.3.  Synthetic pathway of PVA-ADOX conjugates.
Fig.4.  HPSEC chromatograms of PVA ( ), PVA-cis-ADOX ( ) and PVA-trans- ADOX ( ). 
HPSEC was carried out on a TSKge1 G4000PWXL column (7.8 x 300 mm) with 0.2 M NaCl in 0.05 
M phosphate buffer, pH 7.0. PVA-cis- ADOX and PVA-trans- ADOX were spectrophotometrically 









? HPLC?????????????? DOX??????????????? (21)?HPLC
????? DOX??? 4.4 w/w%?????????????? 4.6 w/w%????????
PVA-ADOX?? PVA 1 mol?????????? 62 mol?????????? DOX? 6.1 ~ 
6.4 mol?????????????????
1-4?????
?????????????PVA-ADOX??? DOX?????? Fig. 5?????DOX?
???? pH?????? pH 5?pH 6????????????????????????
??????????pH 5?????PVA-cis-ADOX? PVA-trans-ADOX????????
?????PVA-cis-ADOX? 3 h? PVA-trans-ADOX? 14 h????cis?? trans????
4.7??????????????????PVA-cis-ADOX? pH 6???????PVA-trans-
ADOX???????????????????DOX?????????????????
Fig.5.  Effect of pH on the release of DOX from PVA-cis- ADOX (A) and PVA-trans-ADOX (B). 
The release of DOX from the conjugates was determined in 0.1 M citrate buffer solution (?=0.3) 





?J774.1??? PVA-cis-ADOX?? DOX??????????? DOX?????????
???Fig. 6??DOX?????????? DOX???????????????????
PVA-cis-ADOX?????????????????????????????




Fig.6.  Fluorescence microscopic examination of the cellular distribution of PVA-cis-ADOX (A) 
and DOX (B) in J774.1. Cells (4 x 10
5
) were incubated with PVA-cis-ADOX (20 ?g/ml in DOX 
equivalent) at 37 ? for 6 h. After incubation, the cells were washed three times with PBS (pH 7.4) 

















Fig.7.  Intracellular release of DOX from PVA-cis-ADOX (close column) and PVA-trans-ADOX 
(open column) in J774.1. Cells (4 x 10
5
) were incubated with PVA-ADOX conjugates (125 ?g/ml in 
DOX equivalent) at 37 ? for 6 h. After incubation, the cells were washed and homogenized. The 
amount of DOX was estimated by using a HPLC equipped with a variable-wavelength ß uorescent 
detector. The excitation and emission wavelength were set at 470 nm and 560 nm, respectively. 
Values are given as means ± SE (n = 3). The statistical significance was determined based on 














Fig.8.  Effects of PVA-cis-ADOX ( ? ), PVA-trans-ADOX ( ? ) and DOX ( ? ) on the 
proliferation of J774.1 cells. Cells (5 x 10
3
) were incubated with various drug concentrations for 
5 h and then washed with fresh medium and incubated for another 48 h. After incubation, the 
cells were incubated with [
3
H]uridine for 2 h and harvested. Results are shown as percent of the 








          
?????????????????????????????????Polyethylene glycol








PVA-SPTX????????????Fig. 9??PTX???????????????6.2 w/w 
%???????? PVA 1 mol??? 5.8 mol? PTX??????????????????
???PVA-SPTX??????PTX??? 2 mg/ml??????PTX???? 0.3 ?g/ml??
??????????????????
Fig. 9. Synthetic pathway of PVA-SPTX conjugate.








?1.5 M DENA??????????????????????????? PVA-SPTX??
? PTX???????????PTX? DENA?????1.5 M DENA?? PTX??? 290 
?g/ml ???????????? (38)?DENA?????????????????????
??PVA-SPTX?????? PTX???????????
????????? PTX? pH 7?????????pH 7???????????????
????????PTX???????????????????????? III?????
?????????? (39)???? pH?????PVA-SPTX??? PTX?????????
???? PTX????????????????????????? PTX???????
???????????Fig. 11??
Fig. 10. Three dimensional chromatogram of PVA-SPTX. The retention time of the peak top 
of PVA-SPTX was 8.4 min in the cross section at 227 nm. High-performance size-exclusion 
chromatography was carried out using a HPLC system equipped with a photodiode array 
detector. A 7.8 x 300 mm, TSKgel G4000PWXL column was used at 40 ? . The mobile phase was 
20 % acetonitrile in 50 mM LiCl and the ß ow rate was 1.0 ml/min.
? ?? ?
?????????????????k1???????????k2??????pH????




? [PTX]=k1[PTX]*/(k2? k1)×(exp(? k1t)? exp(? k2t)) ?1?
???? [PTX]? PTX????[PTX]*? PVA-SPTX?????????? PTX???k1?
???????k2???????????
????PTX??????????????
 [PTX]=[PTX]0exp(? k2t)                    ?? ?2?
???? [PTX]0? PTX????????PVA-SPTX?????? PTX???PTX????
???????????????????????????????MULTI????????
? (40)???????? Damping Gauss-Newton??????
?pH 7?? PVA-SPTX??? PTX?????k1 = 0.187 h-1?? PTX??????k2 = 0.00345 
h
-1????? 54 ??????????????????????? 3.7 h??????? 201 
h?????
Fig. 11. Regeneration of PTX from PVA-SPTX in 0.05 M citrate buffer solutions (? = 0.15) of pH 
4 (? ), 5 (? ) or 6 (? ) and in 0.05 M phosphate buffer solutions (? = 0.15) of pH 7 (? ), 8 (? ) 











?[125I]-PVA-SPTX? S180????????????????? Fig. 13????[125I]-PVA-
SPTX??????????????????????????????????????
???????PVA-SPTX? EPR?? (3, 41, 42)?????????????????????
??????
2-5????????
?PVA-SPTX? S180?????????????? Fig. 14???????? PTX?? 25 
mg/kg/d??7 d?10 d?14 d?17 d?21 d?????30 d?????????????PVA-
Fig. 12. pH proÞ le of regeneration rate constant of PTX from PVA-SPTX (? ) and decomposition 
rate constant of PTX (? ) in 0.05 M citrate buffer solutions (? = 0.15) or phosphate buffer 








Fig. 13. Time proÞ le of tissue distribution of 
125
I-PVA-SPTX after intravenous injection (6 mg/kg) 
to mice. ? , plasma; ? , liver; ? , kidney; ? , tumor; ? , spleen; ? , lung; ? , heart. Each 
point represents the mean ± SE of Þ ve mice. 
SPTX???????????????????????????????30 d?????














??????PEG???????????????? DOX??????????? (43, 44)?




?????????? PVA????????????????? PVA?Stearoyl PVA?Oleoyl 
PVA?Cholesteroyl PVA?????????Fig. 15?????????? PVA?????????
Stearoyl PVA???????Oleoyl PVA???????Cholesteroyl PVA???????????
??????????? PVA????????????????? PTX?? PVA????
????????????????
3-3?PNA????
???????? PVA???????????????????? PVA?????? PNA
Fig. 14. Antitumor effect of PVA-SPTX and PTX on implanted S180 tumor. Mice were inoculated 
with S180 cells (1 x 10
6
 cells / mouse) subcutaneously. PVA-SPTX and free PTX were given as 
intermittent intravenous injections on days 7, 10, 14, 17 and 21 after the tumor inoculation. ? , 
PVA-SPTX (25 mg/kg in PTX equivalents); ? , PTX (25 mg/kg); ? , control (5 % glucose). Each 











?????????Fig. 16 ~ 18????????PVA??????????????????
20 ~ 40 ?g/ml??????????????????? PVA???????? PNA???
??????????????
Fig. 15.  Structures of hydrophobized poly(vinyl alcohol)
Table 1.









???? PVA?? PTX?? PVA????????????????????????
Table1.???????????? PVA????????4.3 nm????????????
PVA??????? 13.6 ~ 20.2 nm????PVA???????????????????
???PTX?? PVA????????????83.4 ~ 104.8 nm????? PVA?????
???????????
?PTX???????????????PTX??? 5 mg/ml??????PTX???? 0.3 
?g/ml????????????????????PTX?? PVA?????? PTX?????
HPLC???????PTX in stearoyl PVA 18.8 w/w%?PTX in oleoyl PVA 19.4 w/w%?PTX in 
cholesteroyl PVA 19.5 w/w%??????????? PTX??????????94.0 %?97.0 %?
97.5 %?????










?PTX?? PVA????????????????????????PTX in cholesteroyl 
PVA???????????? PTX??????? PTX???????????????


















































Fig. 19.  Time proÞ le of PTX concentration in the plasma after intravenous administration of 
free PTX (? )?PTX in oleoyl PVA (? ) and PTX in cholesteroyl PVA (? ). Each drug was 
administered to ddY mice at a dose of 25 mg/kg in PTX equivalents. 
? ?? ?
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